Genitourinary Cancer News

Standard cancer care may fail to adequately address the needs of LGBTQ+ individuals, who face substantial disparities in access to screening, treatment and outcomes.

The FDA granted fast track designation to CT-0508 for treatment of patients with solid tumors that overexpress human epidermal growth factor receptor 2.

More than a third of patients with solid tumors showed evidence of antitumor response after treatment with ADP-A2M4CD8, according to data presented at the virtual ESMO Congress.

First-line nivolumab plus ipilimumab conferred durable survival benefit compared with sunitinib for patients with advanced renal cell carcinoma, according to results of the randomized phase 3 CheckMate-214 trial.

The FDA granted full approval to pembrolizumab for first-line treatment of certain patients with advanced urothelial carcinoma, according to the agent’s manufacturer.

Patients with cancer had lower rates of SARS-CoV-2 infection and mortality after two doses vs. one dose of COVID-19 vaccines, according to study results from Centre Léon Bérard Cancer Center published in Annals of Oncology.

The FDA approved nivolumab for adjuvant treatment of patients with surgically resected, high-risk urothelial carcinoma, according to the agent’s manufacturer.

The FDA approved belzutifan for treatment of cancers associated with von Hippel-Lindau disease.

The FDA approved the combination of pembrolizumab and lenvatinib for first-line treatment of adults with advanced renal cell carcinoma.

The FDA granted priority review to pembrolizumab as adjuvant therapy for certain patients with renal cell carcinoma, according to the agent’s manufacturer.